View source for Chemistry:Enavogliflozin

{{Short description|Chemical compound}}
{{Infobox drug
| drug_name         = 
| INN               = 
| type              = <!-- empty -->
| image             = Enavogliflozin.svg
| alt               = 
| caption           = 
<!-- Clinical data -->
| pronounce         = 
| tradename         = 
| Drugs.com         = 
| MedlinePlus       = 
| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AU_comment = 
| pregnancy_category= 
| routes_of_administration = 
| ATCvet            = 
| ATC_prefix        = None <!-- Scheduled to be A10BK09 in 2025 -->
| ATC_suffix        = 
<!-- Legal status -->
| legal_AU          = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_AU_comment  = 
| legal_BR          = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C5, D1, D2, E, F1, F2, F3, F4 -->
| legal_BR_comment  = 
| legal_CA          = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_CA_comment  = 
| legal_DE          = <!-- Anlage I, II, III or Unscheduled -->
| legal_DE_comment  = 
| legal_NZ          = <!-- Class A, B, C -->
| legal_NZ_comment  = 
| legal_UK          = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
| legal_UK_comment  = 
| legal_US          = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_US_comment  = 
| legal_EU          = 
| legal_EU_comment  = 
| legal_UN          = <!-- N I, II, III, IV / P I, II, III, IV -->
| legal_UN_comment  = 
| legal_status      = Investigational<!-- For countries not listed above -->
<!-- Pharmacokinetic data -->
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| metabolites       = 
| onset             = 
| elimination_half-life = 
| duration_of_action= 
| excretion         = 
<!-- Identifiers -->
| synonyms          = DWP16001
| CAS_number        = 1415472-28-4
| UNII              = Z5MR2Y1IJJ
| PubChem           = 71076840
| DrugBank          = 
| ChEMBL = 3703921
| ChemSpiderID = 58891640
<!-- Chemical and physical data -->
| StdInChI=1S/C24H27ClO6/c25-19-15(9-12-1-3-13(4-2-12)14-5-6-14)10-17(16-7-8-30-23(16)19)24-22(29)21(28)20(27)18(11-26)31-24/h1-4,10,14,18,20-22,24,26-29H,5-9,11H2/t18-,20-,21+,22-,24+/m1/s1
| StdInChIKey = KORCWPOBTZTAFI-YVTYUBGGSA-N
| SMILES = C1CC1C2=CC=C(C=C2)CC3=CC(=C4CCOC4=C3Cl)[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O 
| IUPAC_name        = (2''S'',3''R'',4''R'',5''S'',6''R'')-2-[7-Chloro-6-[(4-cyclopropylphenyl)methyl]-2,3-dihydro-1-benzofuran-4-yl]-6-(hydroxymethyl)oxane-3,4,5-triol
| C = 24 | H = 27 | Cl = 1 | O = 6
}}

'''Enavogliflozin''' ('''DWP16001''') is an experimental selective SLC5A2 and [[Chemistry:SGLT2 inhibitor|SGLT2 inhibitor]] developed to treat diabetes and obesity.<ref>{{cite journal |last1=Hwang |first1=Jun Gi |last2=Lee |first2=SeungHwan |last3=Huh |first3=Wan |last4=Han |first4=Jumi |last5=Oh |first5=Jaeseong |last6=Jang |first6=In-Jin |last7=Yu |first7=Kyung-Sang |title=Dose-dependent glucosuria of DWP16001, a novel selective sodium–glucose cotransporter-2 inhibitor, in healthy subjects |journal=British Journal of Clinical Pharmacology |date=September 2022 |volume=88 |issue=9 |pages=4100–4110 |doi=10.1111/bcp.15348|pmid=35395697 |doi-access=free }}</ref><ref>{{cite journal |last1=Kim |first1=Ju-Hyun |last2=Kim |first2=Dong Kyun |last3=Choi |first3=Won-Gu |last4=Ji |first4=Hye-Young |last5=Choi |first5=Ji-Soo |last6=Song |first6=Im-Sook |last7=Lee |first7=Sangkyu |last8=Lee |first8=Hye Suk |title=In Vitro Metabolism of DWP16001, a Novel Sodium-Glucose Cotransporter 2 Inhibitor, in Human and Animal Hepatocytes |journal=Pharmaceutics |date=11 September 2020 |volume=12 |issue=9 |pages=865 |doi=10.3390/pharmaceutics12090865|pmid=32932946 |pmc=7558535 |doi-access=free }}</ref><ref>{{cite journal |last1=Kim |first1=Byungwook |last2=Huh |first2=Ki Young |last3=Hwang |first3=Jun Gi |last4=Nah |first4=JaeJin |last5=Huh |first5=Wan |last6=Cho |first6=Jae Min |last7=Jang |first7=In-Jin |last8=Yu |first8=Kyung-Sang |last9=Kim |first9=Yun |last10=Lee |first10=SeungHwan |title=Pharmacokinetic and pharmacodynamic interaction between DWP16001, an sodium–glucose cotransporter 2 inhibitor and metformin in healthy subjects |journal=British Journal of Clinical Pharmacology |date=April 2023 |volume=89 |issue=4 |pages=1462–1470 |doi=10.1111/bcp.15613|pmid=36422809 |s2cid=253838705 }}</ref><ref>{{cite journal |last1=Rhee |first1=Beomseok |last2=Mahbubur |first2=Rahman Md |last3=Jin |first3=Changfan |last4=Choi |first4=Ji-Soo |last5=Lim |first5=Hyun-Woo |last6=Huh |first6=Wan |last7=Park |first7=Joon Seok |last8=Han |first8=Jumi |last9=Kim |first9=Sokho |last10=Lee |first10=Youngwon |last11=Park |first11=Jinho |title=Evaluation of safety and anti-obesity effects of DWP16001 in naturally obese dogs |journal=BMC Veterinary Research |date=December 2022 |volume=18 |issue=1 |page=237 |doi=10.1186/s12917-022-03324-2|pmid=35733159 |pmc=9214997 |doi-access=free }}</ref><ref>{{cite journal |last1=Yoon |first1=Sukyong |last2=Park |first2=Min Soo |last3=Jin |first3=Byung Hak |last4=Shin |first4=Hyobin |last5=Na |first5=Jaejin |last6=Huh |first6=Wan |last7=Kim |first7=Choon Ok |title=Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium-glucose cotransporter-2 inhibitor, with phentermine in healthy subjects |journal=Expert Opinion on Drug Metabolism & Toxicology |date=3 July 2023 |volume=19 |issue=7 |pages=479–485 |doi=10.1080/17425255.2023.2249397|pmid=37593838 |s2cid=265846294 }}</ref>

==References==
{{reflist}}


[[Category:SGLT2 inhibitors]]
[[Category:Glucosides]]
[[Category:Cyclopropanes]]
[[Category:Chloroarenes]]
[[Category:Benzofurans]]

{{Sourceattribution|Enavogliflozin}}